Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.

Glabellar Lines Clinical Trial

Official title:

Phase 3 Clinical Study of Efficacy and Safety Assessment; Multi-center, Randomized, Blind, and Parallel Control; and Positive Control of Botulax® Injection and BOTOX® for Improvement of Moderate to Severe Glabellar Wrinkles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05380154
• Other study ID #: Botulax-3001
• Status: Completed
• Phase: Phase 3
• Start date: May 9, 2017
• Est. completion date: July 6, 2018

Study information

• Verified date: April 2022
• Source: Hugel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a phase 3 clinical trial of multi-center, random, blinded*, parallel control, and positive control to evaluate the efficacy and safety of Botulax® Injection compared to BOTOX® for improving moderate to severe glabellar wrinkles.

Description:

The case test of 500 qualified test subjects was conducted in 13 institutions nationwide in China. Those who meet all selection criteria and do not meet any of the exclusion criteria are selected as suitable test subjects. The selected test subjects are blinded and divided into the Botulax test group or the BOTOX test group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: July 6, 2018
• Est. primary completion date: January 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Aged 18 - 65 years (inclusive), no gender preference

2. The evaluator at each institution assesses the severity level of glabellar wrinkles at the site in the field when the test subject frowns as much as possible according to the 4-point photographic evaluation table and classifies the subjects with a rating of = 2 (medium or severe).

3. Persons who can follow the test well, fully understand the clinical trial, rationally foresee the cost-effectiveness of injection, and adhere to the study procedure until the end of the clinical trial are selected.

4. The test subjects fully understand the test requirements and voluntarily sign the consent form.

Exclusion Criteria:

1. Subjects who have a history of oversensitivity to the Botulinum Toxin A type, Botulinum Toxin B type, or other control groups of the tested drug substance.

2. Subjects with clear scars, infections, a carcinogenic or cancerous metastatic lesion on the upper part of the face and/or unrecovered wounds on the face.

3. Subjects with skin disease, such as dermatitis and acne, or scar on the face, which the investigator judges can affect the evaluation of treatment effectiveness or safety of the test subject.

4. Subjects who took anticoagulant drugs (e.g., aspirin, nonsteroidal anti-inflammatory drugs, clopidogrel, warfarin, etc.) within two weeks prior to selection; the test subjects who are menstruating can avoid it by delaying the injection of studied products as needed.

5. Subjects who took drugs with muscle relaxation effects (e.g., muscle relaxants, Curare-like substances, anticholinergic drugs, spectinomycin hydrochloride, aminoglycoside-based drugs, polypeptide antibiotics, tetracycline, lincomycin-based drugs, anticholinergics, benzodiazepines and similar drugs, or benzamide drugs) within 4 weeks prior to selection, anticholinergics, benzodiazepines and similar drugs, or benzamide drugs) or are foreseen to use the above drugs during the study period (for 16 weeks after the injection treatment).

6. Subjects who have used external medications (e.g., glucocorticoids or tretinoin ointment) on the upper part of the face within 4 weeks prior to the selection or are foreseen to use the drug on the upper part of the face during the study period (for 16 weeks after the injection treatment).

7. Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period (Botulinum Toxin A type or Botulinum Toxin B type).

8. Subjects who have undergone eye shape correction, laser skin transplantation, skin surgery, IPL, frequency surgery, dermabrasion, chemical dermabrasion, or other laser resolution and nonresolution surgery within 6 months prior to selection or are foreseen to do so during the study period.

9. Subjects who have had injected hyaluronic acid in the upper part of their face within 12 months prior to selection or plan to do it.

10. Subjects who have a history of surgery to remove wrinkles on the face above the eyes or a permanent filling injection.

11. Subjects who plan to undergo a wrinkle removal surgery on their face during the study period, an injection filling of soft tissue for wrinkle removal, or other facial plastic surgeries.

12. Subjects whom the investigator judges to be unsuitable to participate in this study

Related Conditions & MeSH terms

• Glabellar Lines

Intervention

Drug:
• Botulinum Toxin A type for injection (Botulax®)
Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
• Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.

Locations

Country	Name	City	State
Korea, Republic of	Hugel Inc.	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Hugel	Sihuan Pharmaceutical Limited

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Responder rate of improvement in glabellar lines with Physician's rating of line severity	The rate of test subjects receiving 0 or 1 point by the institution evaluator who assesses the glabellar wrinkles (at maximum frown) at the site in week 4.	Week 4
Secondary	Responder rate of improvement in glabellar lines with Physician's rating of line severity	The rate of test subjects receiving 0 or 1 point by the institution evaluator who assesses the glabellar wrinkles (at maximum frown)at the site in weeks 1, 8, 12, and 16 after the treatment	weeks 1, 8, 12, and 16 after the treatment
Secondary	Responder rate of improvement in glabellar lines at rest with Physician's assessment of severity	The rate of test subjects receiving 0 or 1 point by the institution evaluator who assesses the glabellar wrinkles (when at rest) at the site in weeks 1, 4, 8, 12, and 16 after the treatment	weeks 1, 4, 8, 12, and 16 after the treatment
Secondary	Responder rate of improvement in glabellar lines at maximum frown with investigator's photo assessment	The rate of test subjects receiving 0 or 1 point by the Independent Evaluation Committee based on the photo of the glabellar wrinkles (at maximum frown) in weeks 1, 4, 8, 12, and 16 after the treatment	weeks 1, 4, 8, 12, and 16 after the treatment
Secondary	Responder rate of improvement in glabellar lines at rest with investigator's photo assessment	The rate of test subjects receiving 0 or 1 point by the Independent Evaluation Committee based on the photo of the glabellar wrinkles (when at rest) in weeks 1, 4, 8, 12, and 16 after the treatment	weeks 1, 4, 8, 12, and 16 after the treatment
Secondary	Responder rate of improvement in glabellar lines with Subject's improvement assessment	The rate of test subjects who self-assess that the treatment is effective (by giving a score of "+2" or higher) in weeks 1, 4, 8, 12, and 16 after the treatment	weeks 1, 4, 8, 12, and 16 after the treatment
Secondary	Subject's satisfaction rate	The rate of test subjects who are satisfied with the treatment effect (test subject's satisfaction rating of 6 - 7) in weeks 1, 4, 8, 12, and 16 after the treatment	weeks 1, 4, 8, 12, and 16 after the treatment